Pfizer drops plan to study twice-daily obesity pill in late-stage
studies
Send a link to a friend
[December 01, 2023]
(Reuters) - Pfizer said on Friday it would not advance a
twice-daily version of oral weight-loss drug danuglipron into late-stage
studies after most patients in a mid-stage trial dropped out with high
rates of side effects such as nausea and vomiting.
The decision marks a blow to Pfizer's ambitions to become an early
contender in the lucrative market for weight-loss drugs. The company's
shares dropped 2.9% to $29.59 in premarket trading.
Danuglipron belongs to the same class of diabetes and obesity treatments
as Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Mounjaro and
Zepbound.
Pfizer said it would instead focus on a once-daily, modified release
version of danuglipron and "gathering the data to understand its
potential profile". Data on how this version interacts with the human
body is expected sometime next year.
In the current study of the twice-daily version, Pfizer said the drug,
however, met the main goal of reducing weight in adults with obesity and
without type 2 diabetes.
Observed mean weight loss in the trial, across doses, ranged between
6.9% and 11.7% in patients on the drug at 32 weeks, versus weight gain
of 1.4% for placebo.
That compared to a nearly 15% drop observed with the highest dose of Eli
Lilly's once-daily experimental orforglipron pill after 36 weeks of
treatment in a trial of obese or overweight patients.
[to top of second column]
|
A person walks past the Pfizer Headquarters building in the
Manhattan borough of New York City, New York, U.S., November 9,
2020. REUTERS/Carlo Allegri
"We believe an improved once-daily
formulation of danuglipron could play an important role in the
obesity treatment paradigm," Pfizer's Chief Scientific Officer
Mikael Dolsten said in a statement.
Pfizer said while the common side effects in the twice-daily version
study were mild, it saw high rates of those events in the trial.
High discontinuation rates, greater than 50%, were seen across all
doses compared to about 40% with placebo.
It said that up to 73% of patients in the trial had nausea; up to
47% vomiting and up to 25% diarrhea. However, no new safety signals
were observed in the study, Pfizer said.
(Reporting by Manas Mishra in Bengaluru and Michael Erman in New
York; Editing by Shinjini Ganguli)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |